Avantor (AVTR) has returned to investor focus following a recent share price move. The stock closed at US$10.28 as traders consider its mixed return profile over the past year and across longer time frames.

The recent 1 day share price return of 1.98% and 30 day share price return of 22.38% suggest short term momentum is building for Avantor, although the 1 year total shareholder return of 24.02% and 5 year total shareholder return of 70.93% reflect a much weaker long run experience.

If this move has you reassessing your watchlist, it could be a good moment to use a screener to uncover 39 healthcare AI stocks.

With Avantor reporting an intrinsic value estimate that is 29.12% above its recent US$10.28 share price, yet trading slightly above the average analyst target, investors now face a key question: is there genuine value left here or is the market already pricing in future growth?

Most Popular Narrative: 4% Overvalued

Avantor's most followed narrative points to a fair value of about $9.92, which sits slightly below the recent $10.28 share price and frames a modest valuation premium.

The analysts have a consensus price target of $9.92 for Avantor based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $19.0, and the most bearish reporting a price target of just $7.0.

Want to see what sits behind this fair value reset for Avantor? The narrative leans heavily on a profit swing, modest revenue growth, and a re rated earnings multiple. The real intrigue is how these moving parts combine to justify that future earnings profile and valuation anchor.

Result: Fair Value of $9.92 (OVERVALUED)

However, this fair value story for Avantor still leans on assumptions that could be challenged if competitive pricing pressures persist or if bioprocessing demand stays weaker than expected.

Another View On Avantor's Valuation

While the leading Avantor narrative flags the stock as about 4% overvalued relative to a US$9.92 fair value, the SWS DCF model points the other way. On that approach, Avantor at US$10.28 is trading around 29% below an estimated future cash flow value of US$14.50. Which lens do you trust more when the signals conflict?

Next Steps

With mixed signals around Avantor's value and outlook, the key question is how you weigh its potential rewards against the concerns being flagged. To make that call with confidence, review both sides of the story in the detailed breakdown of 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Avantor?

If Avantor has you thinking more seriously about your portfolio, do not stop here. The best opportunities often sit just outside your current watchlist.

• Target dependable income by scanning companies with generous yields and resilient payout histories through the 8 dividend fortresses.
• Spot potential mispricing quickly by running a focused search on companies that appear attractively valued using the 44 high quality undervalued stocks.
• Strengthen your downside protection by filtering for companies with robust finances via the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.